The Elastomer Infusion Pump Market size was valued US$ 1.03 billion in 2021 and is estimated to reach US$ 2.28 billion by 2029, growing at a CAGR of 8.7% during the forecast period (2022-2029).
The elastomer infusion pump is the medical device used to infuse medicines including antibiotics, chemotherapy, cytostatics, analgesics, local anesthetics, and others. It works by creating pressure by an elastomeric layer that that is molded into the inside of the pump. The elastomeric layer becomes stretched whenever the elastomeric pump is filled. It provides intermittent or constant infusions via the intravenous, intra arterially, epidurally, subcutaneous, perineural, intralesional, and another route of administration. It controls the flow rate’s accuracy through the flow restrictor, which is molded into the system’s tubing or placed within the elastomeric reservoir. The flow rate is increased or decreased whenever the elastomer infusion pump is placed above or below the patient.
The global elastomer infusion pump market is growing due to several factors such as rising demand for elastomer infusion pumps in an ambulatory centres and hospitals due to increasing prevalence of chronic disease, various new cost-effective product launches and novel technological advances.
Rising incidence of chronic diseases and various new technological advancements are expected to drive market growth.
The market growth is influenced by the rising demand for elastomer infusion pumps in an ambulatory or immobile centre, hospitals, clinics, and home care centres owing to their advantages such as neither gravity nor electricity-driven, availability of elastomeric pumps in a small size, lightweight, disposable, and portable, easy to operate, longer stability & storage of medicines, and eliminates the possibility of the human errors. These infusion pumps are the preferred choice for the consumers as they can be carried in a pouch or sometimes a pocket. The elastomer infusion pumps also provide storage advantages. These pumps can be easily frozen or refrigerated, depending on the type of medications being used. Moreover, the elastomer infusion pumps have pre-attached tubing that minimizes additional expenses.
The rise in the launch of cost-effective and convenient elastomeric infusion pump products shall boost the market growth. For instance, in April 2021, B. Braun had launched Spaceplus that is a novel infusion pump combined with OnlineSuiteplus a kind of ecosystem that provides various benefits including connectivity, data management, cloud-based applications, excellent therapy and update flexibility.
The market is witnessing technological advancement with the digital platforms for Elastomeric Infusion Pump. For instance, Epic Medical Pte. Ltd’s SMARTeZ Pump allows the medication to be delivered to the patient by positive pressure applied by the elastomeric membrane. It comprises 2 layers of silicone membranes for improving the flow accuracy and reduces the residual volume when the infusion is complete. Moreover, the Mobile Apps are available along with this Elastomeric Infusion Pump to improve patient-user outcomes in alternate sites and at home VSCAN and Chemo CS App. VSCAN provides an assessment of the volume of medication remaining in the pump. SMARTeZ Chemo CS App helps eliminate human errors and improves patient safety with its onboard drug library.
The rising initiatives of several organizations, associations, and institutes to improve the elastomeric infusion pump and address the safety concerns shall stimulate market growth. For instance, the U.S. Food and Drug Administration (FDA) launched the infusion pump improvement initiative to address infusion pump safety problems and foster the development of safer, more effective infusion pumps across the industry. The FDA had established the additional requirements for infusion pump manufacturers to identify the design deficiencies and correct them timely before these deficiencies lead to safety problems. It had also provided the additional design and engineering information as part of their premarket submissions and conduct additional testing of their devices. The FDA had entered into a collaboration with the institutes, foreign regulatory bodies, and manufacturers to facilitate the development of safer and more effective infusion pumps. The FDA is creating awareness regarding mitigating the risks associated with using existing infusion pumps among hospital staff, administrators, and home users.
Scarcity of skilled professionals and software problems are expected to hamper the market growth.
The market is hindered by the lack of skilled staff to manage elastomeric infusion pumps, including filling the devices with medications and using varying infusion rates and concentrations. Moreover, there is a lack of pharmacy involvement in preparing and dispensing the pumps. The other issues associated with the elastomeric infusion pump are software problems, alarm errors, inadequate user interface design, damaged components, and others that could hurt the market.
The global elastomer infusion pump market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.
Product type segment is expected to hold the largest market share in global elastomer infusion pump market
The elastomer infusion pump market is segmented into product types as continuous rate pumps and variable rate pumps. The continuous rate pumps account for the highest market share due to the high adoption of continuous rate elastomer infusion pumps to treat several diseases including cancer and chronic diseases as it provides efficient performance and stability. It is widely used for post-operative pain management. The market is dominated by the availability of several continuous rates of elastomer infusion pumps. For instance, Smiths Medical’s Neofuser is a single-use, portable elastomeric infusion pump that provides the medication at a continuous pre-fixed flow. It is used to infuse chemotherapy, antibiotic therapy, analgesic therapy, and other general intravenous, intraarterial, subcutaneous, epidural, perineural, and intralesional infusions. Smith Medical’s Neofuser Vario is a single-use, portable elastomeric multi-rate infusion pump used for systemic or regional preoperative and postoperative pain management therapy. It is available in different reservoir sizes to select 7 different flow rates and stop the flow with a detachable key.
The variable rate pumps segment is expected to have positive market growth owing to the rising uptake of patient-controlled analgesia (PCA) elastomeric pumps, i.e., elastomeric pumps with a bolus, as it enables to change the flow rate according to the individual pain relief requirements and effective in reducing the hospital stay and lowering the pain. For instance, Avanos Medical, Inc’s On-Q Pump with Select-A-Flow Variable Rate Controller and On-demand Bolus Button is a non-narcotic elastomeric pump that automatically delivers a regulated flow of local anesthetic to a patient’s surgical site or near nerves. It comprises the variable rate controller that provides the flow rate to be changed as per the patients’ individual pain relief requirements and a bolus device that allows for breakthrough pain relief on demand by the patient or healthcare provider. This device has reduced the hospital stay by 1.1 days sooner, 69% lower pain scores, high satisfaction scores, and better pain management with fewer side effects.
Further, the market is also classified based on pain management, infection management, chemotherapy, etc. The pain management segment accounts for the highest market share due to the elastomer infusion pump’s high usage to deliver both anesthetics and analgesics directly to the lesion or inflamed tissue. These devices help control acute pain and improve the patient’s quality of life by maintaining its plasma level stability and analgesia. There is a rise in the approval of innovative and novel elastomer infusion pumps for pain management.
The chemotherapy segment is expected to have a positive market share due to an elastomer infusion pump’s rising uptake for delivering chemotherapy. The increasing incidence of cancer as the elastomer infusion pump effectively delivers chemotherapy directly into the bloodstream and reducing the risk of developing occlusion. There is an increase in the number of companies developing the elastomer infusion pump for chemotherapy infusion. Halyard Health, Baxter International Inc, Epic Medical, Nipro Medical Corporation are the major players for the elastomer infusion pump for chemotherapy infusion. For instance, Nipro’s Surefuser is a lightweight, single-use device for the safe delivery of chemotherapy treatments and other drugs administered intravenously. It reduces the risk of involuntary exposure to the medications. Halyard Health provides the home pump C-Series elastomer infusion pump for continuous infusion with delivery times ranging from 1 to 11 days for chemotherapy.
North America region holds the largest market share in the global elastomer infusion pump market
By region, the elastomer infusion pump market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the elastomer infusion pump market due to high hospital stay with the rising prevalence of chronic diseases. According to the Agency for Healthcare Research and Quality (AHRQ), approximately more than seven million people are admitted to the hospital every year. Chronic diseases are the leading cause of mortality and morbidity. According to the Centres for Disease Control & Prevention (CDC), 2021 report approximately 6 out of 10 people have a chronic disease. Around 4 out of 10 people have two or more chronic diseases. More than 1 in 7 of US adults that is around 15% or 37 million adults are estimated to have CKD. 9 out of 10 people with CKD are unaware about their condition. The rise in the approval of the novel elastomer infusion pump products with technological advancement and product innovation & diversification shall stimulate market growth.
The Asia-Pacific market is expected to have positive market growth owing to the increase in the number of companies manufacturing the elastomer infusion pump. Manufacturers are focusing on bundling associated accessories and IV drugs to increase market penetration.
Developing countries such as China and India are expected to have substantial market growth owing to their increasing reliance on direct sales visits. The direct sales personnel also provide training to the staff and homecare settings to administer drugs to patients using elastomeric infusion pumps. The rising uptake of pain management drugs and chemotherapy drugs shall increase the elastomer infusion pump’s demand. The rising number of post-operative early discharges from hospitals shall boost the demand for wearable disposable ambulatory elastomeric infusion pumps. Moreover, the growing adoption of elastomeric infusion pumps in-home care settings, especially for older adults, provides their homes’ comfort. The growing awareness regarding the elastomer infusion pump shall fuel the market growth over the forecasted period.
The elastomer infusion pump market is highly competitive with the presence of several international and local market players. Product diversification, cost-effective products, revenue generation, and opportunities intensify the market competition. B Braun Melsungen AG, Baxter International Inc, Halyard Health, Heka Healthcare, Nipro Medical Corporation, Palex Medical SA, and Hospira Inc (Pfizer Inc.) are the leading companies with a significant market share.
Companies are using technological advancement, product diversification, novel product development, and market expansion strategies. For instance, in February 2020, LTR Medical had entered into an exclusive distribution agreement with Woo Young Medical to distribute their new generation of elastomeric infusion technologies into the Australian market.
The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for elastomer infusion pump and their expansion across the globe. For instance, in Nov 2020, Ambu Inc. announced their contract with Intalere that will work for pain care management solutions. Intlere is going to receive Ambu ACTion TM block pain pump.
Key Companies to Watch
B Braun Melsungen AG:
Overview: B. Braun is German company that manufactures medical and pharmaceuticals device. Headquartered in Melsungen, Germany and founded in 1839. They provide services in around 60 countries that employees around 63,000 people. They have aroubd 5,000 variety of healthcare products.
Product Type Portfolio:
Easypump ST/LT: These elastomeric infusion pumps are developed to provide clinicians with the alternative to give the patients pre-determined medication amounts with an accurate and continuous system. It can be used in hospital as well as home.
Key Developments: B. Braun announced today that US FDA cleared its SpaceStation MRI for Space infusion pumps to deliver continuous medication to patients within the MRI system.
The global elastomer infusion pump market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.